The keloid phenomenon: Progress toward a solution

Clinical Anatomy

Volumn 20, Issue 1, 2007, Pages 3-14

  Louw, Louise ^a,b  

^a UNIVERSITY OF THE FREE STATE   (South Africa)

^b UNIVERSITY OF THE FREE STATE   (South Africa)

Author keywords

Biological activities; Etiology; Fatty acid adjuvant therapy; Histopathogenesis; History; Keloids; Multimodal therapies

Indexed keywords

ARACHIDONIC ACID; BLEOMYCIN; COLLAGEN; CORTICOSTEROID; CYCLOOXYGENASE 2; CYTOKINE; FATTY ACID; FISH OIL; FREE RADICAL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G; LINOLEIC ACID; LIPID; LIPOXYGENASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOMYCIN C; OLEIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROPYLENE GLYCOL; PROSTAGLANDIN E2; PROTEIN P53; TRACE ELEMENT; TRANILAST; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR AP 1; TRANSFORMING GROWTH FACTOR BETA; TRIAMCINOLONE; UNINDEXED DRUG; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; CELL FUNCTION; CLINICAL FEATURE; CRYOTHERAPY; ENZYME ACTIVITY; ENZYME REGULATION; FIBROBLAST; GENE CONTROL; HEREDITY; HISTOLOGY; HISTORY OF MEDICINE; HUMAN; HYPERTROPHIC SCAR; HYPOXIA; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; KELOID; LOW LEVEL LASER THERAPY; NUTRITION; OXIDATION; PATHOGENESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SKIN SURGERY; THEORY; WOUND HEALING IMPAIRMENT;

ANIMALS; HUMANS; KELOID; WOUND HEALING;

EID: 33845450616     PISSN: 08973806     EISSN: 10982353     Source Type: Journal    
DOI: 10.1002/ca.20374     Document Type: Review

References (128)

1. Akasaka Y, Ishikawa Y, Ono I, Fujita K, Masuda T, Asuwa N, Inuzuka K, Kiguchi H, Ishii T. 2000. Enhanced expression of caspase-3 in hypertophic scars and keloid: Induction of caspase-3 and apoptosis in keloid fibroblasts in vitro. Lab Invest 80:345-357.
2. Akasaka Y, Fujita K, Ishikawa Y, Asuwa N, Inuzuka K, Ishihara M, Ito M, Masuda T, Akishima Y, Zhang L, Ito K, Ishii T. 2001. Detection of apoptosis in keloids and a comparative study on apoptosis between keloids, hypertrophic scars, normal healed flat scars and dermatofibroma. Wound Repair Regen 9:501-506.
3. Aktas H, Halperin JA. 2004. Translational regulation of gene expression by omega-3 fatty acids. J Nutr 134:S2487-S2491.
4. Alaish SM, Yager DR, Diegelmann RF, Cohen IK. 1995. Hyaluronic acid metabolism in keloid fibroblasts. J Pediatr Surg 30:949-952.
5. Alster TS, Tanzi EL. 2003. Hypertrophic scars and keloids. Am J Clin Dermatol 4:235-243.
6. Appleton I, Brown NJ, Willoughby DA. 1996. Apoptosis, necrosis, and proliferation: Possible implications in the etiology of keloids. Am J Pathol 149:1441-1447.
7. Babcock TA, Helton WS, Anwar KN, Zhao YY, Espat NJ. 2004. Synergistic anti-inflammatory activity of omega-3 lipid and rofecoxib pretreatment on macrophage proinflammatory cytokine production occurs via divergent NF-κβ activation. JPEN J Parenter Enteral Nutr 28:232-239.
8. Babu M, Diegelmann R, Oliver N. 1989. Fibronectin is overproduced by keloid fibroblasts during abnormal wound healing. Mol Cell Biol 4:1642-1650.
9. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. 2003. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci USA 100:1751-1756.
10. Bartsch H, Nair J, Owen RW. 1999. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: Emerging evidence for their role as risk modifiers. Carcinogenesis 20:2209-2218.
11. Berbert AA, Kondo CR, Almendra CL, Matsuo T, Dichi I. 2005. Supplementation of fish oil and olive oil in patients with rheumatoid arthritis. Nutrition 21:131-136.
12. Berman B, Villa AM, Ramirez CC. 2005. Novel opportunities in the treatment and prevention of scarring. J Cutan Med Surg 8:32-36.
13. Bettinger DA, Yager DR, Diegelmann RF, Cohen IK. 1996. The effect of TGF-β on keloid fibroblast proliferation and collagen synthesis. Plast Reconstr Surg 98:827-833.
14. Boone DL, Lee EG, Libby S, Gibson PJ, Chien M, Chan F, Madonia M, Burkett PR, Ma A. 2002. Recent advances in understanding NF-κB regulation. Inflamm Bowel Dis 8:201-212.
15. Carroll LA, Hanasono MM, Mikulec AA, Kita M, Koch RJ. 2002. Triamcinolone stimulates bFGF production and inhibits TGF-β1 production by human dermal fibroblasts. Dermatol Surg 28:704-709.
16. Cawood AL, Carroll MP, Wootton SA, Calder PC. 2005. Is there a case for n-3 fatty acid supplementation in cystic fibrosis? Curr Opin Clin Nutr Metab Care 8:153-159.
17. Chait LA, Kadwa MA. 1988. Hypertrophic scars and keloids: Cause and management - current concepts. S Afr J Surg 26:95-98.
18. Chau D, Mancoll JS, Lee S, Zhao J, Phillips LG, Gittes GK, Longaker MT. 1998. Tamoxifen downregulates TGF-β production in keloid fibroblasts. Ann Plast Surg 40:490-493.
19. Chen DW, Fei ZW, Zhang YC, Ou JM, Xu J. 2005. Role of enteral immunonutrition in patients with gastric carcinoma undergoing major surgery. Asian J Surg 28:121-124.
20. Chin GS, Liu W, Peled Z, Lee TY, Steinbrech DS, Hsu M, Longaker MT. 2001. Differential expression of transforming growth factor-β receptors I and II and activation of Smad 3 in keloid fibroblasts. Plast Reconstr Surg 108:423-429.
21. Cleland LG, James MJ, Keen H, Danda D, Caughey G, Proudman SM. 2005. Fish oil- an example of an anti-inflammatory food. Asia Pac J Clin Nutr 14:S66-S71.
22. Clarke SD, Jump DB. 1993. Regulation of gene transcription by polyunsaturated fatty acids. Prog Lipid Res 32:139-149.
23. Cobbold CA, Sherratt JA. 2000. Mathematical modelling of nitric oxide activity in wound healing can explain keloid and hypertrophic scarring. J Theor Biol 204:257-288.
24. Conklin KA. 2002. Dietary polyunsaturated fatty acids: Impact on cancer chemotherapy and radiation. Altern Med Rev 7:4-21.
25. Daian T, Ohtsuru A, Rogounovitch T, Ishihara H, Hirano A, Akiyama-Uchida Y, Saenko V, Fujii T, Yamashita S. 2003. Insulin-like growth factor-I enhances transforming growth factor-β-induced extracellular matrix protein production through the p38/ activating transcription factor-2 signaling pathway in keloid fibroblasts. J Invest Dermatol 120:956-962.
26. Darlington LG, Stone TW. 2001. Antioxidants and fatty acids in the amelioration of rheumatoid arthritis and related disorders. Br J Nutr 85:251-269.
27. Darzi MA, Chowdri NA, Kaul SK, Khan M. 1992. Evaluation of various methods of treating keloids and hypertrophic scars: A 10-year follow-up study. Br J Plast Surg 45:374-379.
28. Das UN. 1991. Interaction(s) between essential fatty acids, eicosanoids, cytokines, growth factors and free radicals: Relevance to new therapeutic strategies in rheumatoid arthritis and other collagen vascular diseases. Prostaglandins Leukot Essent Fatty Acids 44:201-210.
29. Datuba-Brown DD. 1990. Keloids: A review of the literature. Br J Plast Surg 43:70-77.
30. Datuba-Brown DD, Blight A. 1990. Inhibition of human fibroblast growth in vitro by a snake oil. Br J Plast Surg 43:183-186.
31. de Almeida OM, Braz JC, Jorgetti C, de Lemos RG, Neves RI. 2000. Treatment of extensive sternum keloid scar with surgical removal and immediate reconstruction with skin flaps from a combined mammaplasty. Plast Reconstr Surg 105:2452-2454.
32. de Pablo MA, Puertollano MA, de Clenfuegos GA. 2002. Biological and clinical significance of lipids as modulators of immune system functions. Clin Diag Lab Immunol 9:945-950.
33. Doyle-Lloyd DJ, White JA. 1991. Keloids. J La State Med Soc 143:9-12.
34. English RS, Shenefeldt PD. 1999. Keloids and hypertrophic scars. Dermatol Surg 25:631-638.
35. Farreras N, Artigas V, Cardona D, Rius X, Trias M, Gonzalez JA. 2005. Effect of early postoperative enteral immunonutrition on wound healing in patients undergoing surgery for gastric cancer. Clin Nutr 24:55-65.
36. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF. 2002. Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 6:283-294.
37. Field CJ, Schley PD. 2004. Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: Lessons from n-3 fatty acids. Am J Clin Nutr 79:51190-51198.
38. Granstein RD, Flotte TJ, Amento EP. 1990a. Interferons and collagen production. J Invest Dermatol 95:S75-S80.
39. Granstein RD, Rook A, Flotte TJ, Haas A, Gallo RL, Jaffe HS, Amento EP. 1990b. A controlled trial of intralesional recombinant interferon-γ in the treatment of keloidal scarring. Arch Dermatol 126:1295-1302.
40. Gueck T, Seidel A, Baumann D, Meister A, Fuhrmann H. 2004. Alterations of mast cell mediator production and release by γ-linolenic and docosahexaenoic acid. Vet Dermatol 15:309-314.
41. Hardman WE. 2004. (n-3) fatty acids and cancer therapy. J Nutr 134:S3427-S3430.
42. Har-Shai Y, Amar M, Sabo E. 2003. Intralesional cryotherapy for enhancing the involution of hypertrophic scars and keloids. Plast Reconstr Surg 111:1841-1852.
43. Heyland D, Dhaliwal R. 2005. Immunonutrition in the critically ill: From old approaches to new paradigms. Intensive Care Med 31:501-503.
44. Horrobin DF. 1992. Nutritional and medical importance of γ-linolenic acid. Prog Lipid Res 31:163-194.
45. Horrobin DF. 1993. Medical uses of essential fatty acids. Vet Dermatol 4:161-166.
46. Hsu TC, Young MR, Cmarik J, Colburn NH. 2000. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-κB)-dependent transcriptional events in carcinogenesis. Free Radic Biol Med 28:1338-1348.
47. Jacob SE, Berman B, Nassiri M, Vincek V. 2003. Topical application of imiquimod 5% cream to keloids alters expression genes associated with apoptosis. Br J Dermatol 149:62-65.
48. Kauh YC, Rouda S, Mondragon G, Tokarek R, diLeonardo M, Tuan RS, Tan EML. 1997. Major suppression of pro-α 1 (I) type I collagen gene expression in the dermis after keloid excision and immediate intrawound injection of triamcinolone acetonide. J Am Acad Dermatol 37:586-589.
49. Kelly AP. 1988. Keloids. Dermatol Clin 6:413-424.
50. Kelley DS. 2001. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 17:669-673.
51. Kim DY, Kim ES, Eo SR, Kim KS, Lee SY, Cho BH. 2004. A surgical approach for earlobe keloid: Keloid fillet flap. Plast Reconstr Surg 113:668-1674.
52. Kischer CW. 1992. The microvessels in hypertrophic scars, keloids and related lesions: A review. J Submicrosc Cytol Pathol 24:281-296.
53. Kischer CW, Shetlar MR, Shetlar CL, Chvapil M. 1983. Immunoglobulins in hypertrophic scars and keloids. Plast Reconstr Surg 71:821-825.
54. Kulp SK, Lin HP, Chen CS. 2002. Cyclooxygenase-2 in cancer: A role yet to be defined. In: Huang YS, Lin SJ, Huang PC. (eds.) Essential Fatty Acids and Eicosanoids. Champaign, Illinois: AOCS Press. p 155.
55. Kuo YR, Wu WS, Jeng SF, Huang HC, Yang KD, Sacks JM, Wang FS. 2005a. Activation of ERK and p38 kinase mediated keloid fibroblast apoptosis after flashlamp pulsed-dye laser treatment. Lasers Surg Med 36:31-37.
56. Kuo YR, Wu WS, Jeng SF, Wang FS, Huang HC, Lin CZ, Yang KD. 2005b. Suppressed TGF-β1 expression is correlated with upregulation of matrix metalloproteinase-13 in keloid regression after flashlamp pulsed-dye laser treatment. Lasers Surg Med 36:38-42.
57. Larrabee WF Jr, East CA, Jaffe HS, Stephenson C, Peterson KE. 1990. Intralesional interferon γ treatment for keloids and hypertrophic scars. Arch Otolaryngol Head Neck Surg 116:1159-1162.
58. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. 2004. Dietary long-chain n-3 fatty acids for the prevention of cancer: A review of potential mechanisms. Am J Clin J Nutr 79:935-945.
59. Lawrence WT. 1991. In search of the optimal treatment of keloids: Report of a series and a review of the literature. Ann Plast Surg 27:164-178.
60. Lee TY, Chin GS, Kim WJ, Chau D, Gittes GK, Longaker MT. 1999. Expression of transforming growth factor β 1, 2 and 3 proteins in keloids. Ann Plast Surg 43:179-184.
61. Lee Y, Minn KW, Baek RM, Hong JJ. 2001a. A new surgical treatment of keloid: Keloid core excision. Ann Plast Surg 46:135-140.
62. Lee JY, Sohn KH, Rhee SH, Hwang D. 2001b. Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem 276:16683-16689.
63. Llor X, Pons E, Roca A, Alvarez M, Mane J, Fernandez-Banares F, Gassull MA. 2003. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutr 22:71-79.
64. Louw L. 2000a. Keloids in rural black South Africans. Part 1: General overview and essential fatty acid hypotheses for keloid formation and prevention. Prostaglandins Leukot Essent Fatty Acids 63:237-245.
65. Louw L. 2000b. Keloids in rural black South Africans. Part 3: A lipid model for the prevention and treatment of keloid formations. Prostaglandins Leukot Essent Fatty Acids 63:255-262.
66. Louw L. 2003. The keloid story based on essential fatty acids then and now. In: Huang YS, Lin SJ, Huang PC. (eds.) Essential Fatty Acids and Eicosanoids. Champaign, Illinois: AOCS Press. p 285-289.
67. Louw L, Dannhauser A. 2000. Keloids in rural black South Africans. Part 2: Dietary fatty acid intake and total phospholipid fatty acid profile in the blood of keloid patients. Prostaglandins Leukot Essent Fatty Acids 63:247-253.
68. Louw L, Engelbrecht AM, Cloete F, van der Westhuizen JP, Dumas L. 1997a. Impairment in the fatty acid composition of keloids. Adv Exp Med Biol 400B:905-910.
69. Louw L, van der Westhuizen JP, Duyvene de Wit L, Edwards G. 1997b. Keloids: Peripheral and central differences in cell morphology and fatty acid compositions of lipids. Adv Exp Med Biol 407:515-520.
70. Marneros AG, Norris JEC, Olsen BR, Reichenberger E. 2001. Clinical genetics of familial keloids. Arch Dermatol 137:1429-1434.
71. Matsuoka LY, Uitto J, Wortsman J, Abergel RP, Dietrich J. 1988. Ultrastructural characteristics of keloid fibroblasts. Am J Dermatopathol 10:505-508.
72. Marcelo CL, Duell EA, Rhodes LM, Dunham WR. 1992. In vitro model of essential fatty acid deficiency. J Invest Dermatol 99:703-708.
73. McEntee MF, Whelan J. 2002. Dietary polyunsaturated fatty acids and colorectal neoplasia. Biomed Pharmacother 56:380-387.
74. Melis MP, Murru E, Angioni E, Carta G, Banni S. 2002. Does metabolism of conjugated linoleic acid play a role in its biological activities? In: Huang YS, Lin SJ, Huang PC. (eds.) Essential Fatty Acids and Eicosanoids. Champaign, Illinois: AOCS Press. p 339-342.
75. Messadi DV, Doung HS, Zhang Q, Kelly AP, Tuan TL, Reichenberger E, Le AD. 2004. Activation of INF-κB signal pathways in keloid fibroblasts. Arch Dermatol Res 296:125-133.
76. Meyer LJ, Russell SB, Russell JD, Trupin JS, Egbert BM, Shuster S, Stern R. 2000. Reduced hyaluronan in keloid tissue and cultured keloid fibroblasts. J Invest Dermatol 114:953-959.
77. Mori TA, Beilin LJ. 2004. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 6:461-467.
78. Moulin V, Larochelle S, Langlois C, Thibault I, Lopez-Valle CA, Roy M. 2004. Normal skin wound and hypertrophic scar myofibroblasts have differential responses to apoptotic inductors. J Cell Physiol 198:350-358.
79. Murakami T, Yoshioka M, Yumoto R, Higashi Y, Shigeki S, Ikuta Y, Yata N. 1998. Topical delivery of keloid therapeutic drug, tranilast, by combined use of oleic acid and propylene glycol as a penetration enhancer: Evaluation by skin microdialysis in rats. J Pharm Pharmacol 50:49-54.
80. Murray JC, Pollack SV, Pinnell SR. 1981. Keloids: A review. J Am Acad Dermatol 4:461-470.
81. Nedelec B, Ghahary A, Scott PG, Tredget EE. 2000. Control of wound contraction. Basic and clinical features. Hand Clin 16:289-302.
82. Nedelec B, Shankowsky H, Scott PG, Ghahary A, Tredget EE. 2001. Myofibroblasts and apoptosis in human hypertrophic scars: The effect of interferon-α2b. Surgery 130:798-808.
83. Nemeth AJ. 1993. Keloids and hypertrophic scars. J Dermatol Surg Oncol 19:738-746.
84. Oh R. 2005. Practical applications of fish oil (Ω-3 fatty acids) in primary care. J Am Board Fam Pract 18:28-36.
85. Pégorier JP, Le May C, Girard D. 2004. Control of gene expression by fatty acids. J Nutr 134:S2444-S2449.
86. Phan TT, See P, Tran E, Nguyen TT, Chan SY, Lee ST, Huynh H. 2003a. Suppression of insulin-like growth factor signalling pathway and collagen expression in keloid-derived fibroblasts by quercetin: its therapeutic potential use in the treatment and/or prevention of keloids. Br J Dermatol 148:544-552.
87. Phan TT, Sun L, Bay BH, Chan SY, Lee ST. 2003b. Dietary compounds inhibit proliferation and contraction of keloid and hypertrophic scar-derived fibroblasts in vitro: Therapeutic implication for excessive scarring. J Trauma 54:1212-1224.
88. Placik OJ, Lewis VL Jr. 1992. Immunologic associations of keloids. Surg Gynecol Obstet 175:185-193.
89. Ragoowansi R, Cornes PG, Moss AL, Glees JP. 2003. Treatment of keloids by surgical excision and immediate postoperative single-fraction radiotherapy. Plast Reconstr Surg 111:1853-1859.
90. Rao CV, Hirose Y, Indranie C, Reddy BS. 2001. Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res 61:1927-1933.
91. Roche HM. 2004. Dietary lipids and gene expression. Biochem Soc Trans 32:999-1002.
92. Rockwell WB, Cohen IK, Ehrlich HP. 1989. Keloids and hypertrophic scars: A comprehensive review. Plast Reconstr Surg 84:827-837.
93. Roynette CE, Calder PC, Dupertuis YM, Pichard C. 2004. n-3 Polyunsaturated fatty acids and colon cancer prevention. Clin Nutr 23:139-151.
94. Rumalla VK, Borah GL. 2001. Cytokines, growth factors, and plastic surgery. Plast Reconstr Surg 108:719-733.
95. Sampath H, Ntambi JM. 2004. Polyunsaturated fatty acid regulation of gene expression. Nutr Rev 62:333-339.
96. Sanders KW, Gage-White L, Stucker FJ. 2005. Topical mitomycin C in the prevention of keloid scar recurrence. Arch Facial Plast Surg 7:172-175.
97. Santucci M, Borgognoni L, Reali UM, Gabbiani G. 2001. Keloids and hypertrophic scars of Caucasians show distinctive morphological and immunophenotypic profiles. Virchows Arch 438:457-463.
98. Sardesai VM. 1992. The essential fatty acids. Nutr Clin Pract 7:179-186.
99. Seo T, Blaner WS, Deckelbaum RJ. 2005. Omega-3 fatty acids: Molecular approaches to optimal biological outcomes. Curr Opin Lipidol 16:11-18.
100. Shaffer JJ, Taylor SC, Cook-Bolden F. 2002. Keloidal scars: A review with a critical look at therapeutic options. J Am Acad Dermatol 46:S63-S97.
101. Shakespeare PG, Strange RE. 1981. Linoleic acid in hypertrophic scars. Burns 9:7-12.
102. Shishodia S, Aggarwal BB. 2004. Nuclear factor-κB: A friend or a foe in cancer? Biochem Pharmacol 68:1071-1080.
103. Steinbrech DS, Mehrara BJ, Chau D, Rowe NM, Chin G, Lee T, Saadeh PB, Gittes GK, Longaker MT. 1999. Hypoxia upregulates VEGF production in keloid fibroblasts. Ann Plast Surg 42:514-520.
104. Stucker FJ, Shaw GY. 1992. An approach to management of keloids. Arch Otolaryngol Head Neck Surg 118:63-67.
105. Subbaramaiah K, Dannenberg AJ. 2003. Cyclooxygenase 2: A molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24:96-107.
106. Surh YJ, Na HK. 2002. Cyclooxygenase-2 as a putative target for cancer chemoprevention by some anti-inflammatory phytochemicals. In: Huang YS, Lin SJ, Huang PC. (eds.) Essential Fatty Acids and Eicosanoids. Champaign, Illinois: AOCS Press. p 146.
107. Suzawa H, Kikuchi S, Arai N, Koda A. 1992. The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol 60:91-96.
108. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. 2004. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer treatment. Mol Cancer Ther 3:215-221.
109. Szulgit G, Rudolph R, Wandel A, Tenenhaus M, Panos R, Gardner H. 2002. Alterations in fibroblast α1β1 integrin collagen receptor expression in keloids and hypertrophic scars. J Invest Dermatol 118:409-415.
110. Talmi YP, Orenstein A, Wolf M, Kronenberg J. 2005. Use of mitomycin C for treatment of keloid: A preliminary report. Otolaryngol Head Neck Surg 132:598-601.
111. Teofoli P, Motoki K, Lotti TM, Uitto J, Mauviel A. 1997. Propiomelanocortin (POMC) gene expression by normal skin and keloid fibroblasts in culture: Modulation by cytokines. Exp Dermatol 6:111-115.
112. Teofoli P, Barduagni S, Ribuffo M, Campanella A, De Pita O, Puddu P. 1999. Expression of Bcl-2, p53, c-jun and c-fos protooncogenes in keloids and hypertrophic scars. J Dermatol Sci 22:31-37.
113. Tredget EE, Nedelec B, Scott PG, Ghahary A. 1997. Hypertrophic scars, keloids, and contractures: The cellular and molecular basis for therapy. Surg Clin North Am 77:701-730.
114. Tritto M, Kanat IO. 1991. Management of keloids and hypertrophic scars. J Am Podiatr Med Assoc 81:601-605.
115. Tuan TL, Nichter LS. 1998. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 4:19-24.
116. Wahle KW, Heys SD, Rotondo D. 2004. Conjugated linoleic acids: Are they beneficial or detrimental to health? Prog Lipid Res 43:553-587.
117. Watkins BA, Li Y, Lippman HE, Feng S. 2003. Modulatory effect of omega-3 polyunsaturated fatty acids on osteoblast function and bone metabolism. Prostaglandins Leukot Essent Fatty Acids 68:387-398.
118. Wilgus TA, Vodovotz Y, Vittadini E, Clubbs EA, Oberyszyn TA. 2003. Reduction of scar formation in full-thickness wounds with topical celecoxib treatment. Wound Repair Regen 11:25-34.
119. Wong KW. 2005. Clinical efficacy of n-3 fatty acid supplementation in patients with asthma. J Am Diet Assoc 105:98-105.
120. Wu D. 2004. Modulation of immune and inflammatory responses by dietary lipids. Curr Opin Lipidol 15:43-47.
121. Wynter MP, Russell ST, Tisdale MJ. 2004. Effect of n-3 fatty acids on the antitumour effects of cytotoxic drugs. In Vivo 18:543-547.
122. Yagi KI, Dafalla AA, Osman AA. 1979. Does an immune reaction to sebum in wounds cause keloid scars? Beneficial effect of desensitisation. Br J Plast Surg 32:223-225.
123. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. 1994. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem 116:892-897.
124. Yang GP, Lim IJ, Phan TT, Lorenz HP, Longaker MT. 2003. From scarless fetal wounds to keloids: Molecular studies in wound healing. Wound Repair Regen 11:411-418.
125. Yaqoob P. 2004. Fatty acids and the immune system: From basic science to clinical applications. Proc Nutr Soc 63:89-104.
126. Younai S, Nichter LS, Wellisz T, Reinisch J, Nimni ME, Tuan TL. 1994. Modulation of collagen synthesis by transforming growth factor-β in keloid and hypertrophic scar fibroblasts. Ann Plast Surg 33:148-151.
127. Zhang Q, Wu Y, Ann DK, Messadi DV, Tuan TL, Kelly AP, Bertolami CN, Le AD. 2003. Mechanisms of hypoxic regulation of plasminogen activator inhibitor-1 gene expression in keloid fibroblasts. J Invest Dermatol 121:1005-1012.
128. Zurier B. 1991. Essential fatty acids and inflammation. Ann Rheum Dis 50:745-746.